

Donald G. Ainscow | Of Counsel  
Corporate

200 Crescent Court  
Dallas, TX 75201  
+1.972.850.1474  
[donald.ainscow@blankrome.com](mailto:donald.ainscow@blankrome.com)

photo coming soon

Donald Ainscow has more than 15 years of experience advising clients on corporate, mergers and acquisitions, securities, financing, governance, and general business matters. He has a particular emphasis on representing public and private companies in complex mergers, acquisitions, venture capital, and joint venture transactions.

Additionally, Donald has extensive experience representing public and private companies in equity and debt securities financings; representing venture capital funds, private equity funds, and other private investors in connection with their seed and venture financings and exit transactions; counseling boards of directors on corporate governance and fiduciary duties; and advising public companies with respect to their public reporting and disclosure obligations. Donald represents clients in a wide variety of sectors, including life sciences, technology, and healthcare.

## Select Engagements

### Representative experience in M&A transactions:

- A global medical device company in the global carve-out of its former renal care business and the formation of an independent new company committed to kidney health technology solutions.
- A global communications company in its divestiture of assets and simultaneous investment in a private company acquiring a digital signal processing (DSP) business.
- A market-leading clinical cloud solutions company in its public merger with a French software company in a deal worth \$5.8 billion on an enterprise value

basis. Advised on numerous M&A transactions until the sale by merger in 2019.

- A manufacturer of high-performance industrial laser sources in its \$942 million sale by public merger to a competitor.
- A leading eye care company in its acquisition of a medical device company for up to \$250 million in cash and contingent consideration.
- An international pharmaceutical company in connection with divestitures of certain product lines.
- A medical provider in the spin-off of its hospitals and remaining health care operations and activities from ownership and control by a university.

### **Representative experience in securities transactions and public company governance matters:**

- U.S. technology companies in their IPOs and follow-on public offerings.
- Public companies on various equity and debt financings, securities law compliance, and corporate governance matters.
- Dual-listed Canadian public companies in a variety of securities, corporate governance, and reorganization matters.

### **Admissions**

- California
- New York
- Texas

### **Education**

- University of Warwick, LLB, with honors
- Duke University School of Law, LLM

### **Recognitions**

- 2020–2021, “Rising Star” Texas, M&A, *IFLR 1000 United States*, listed in *Euromoney Institutional Investor PLC*
- 2019–2020, “Texas Rising Stars, M&A,” listed in *Thomson Reuters*
- 2011–2017, “New York Rising Star,” listed in *Thomson Reuters*